Compare · AMPH vs JNJ
AMPH vs JNJ
Side-by-side comparison of Amphastar Pharmaceuticals Inc. (AMPH) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMPH and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $452.25B, about 362.7x AMPH ($1.25B).
- Over the past year, AMPH is down 12.1% and JNJ is up 46.5% - JNJ leads by 58.6 points.
- JNJ has been more active in the news (13 items in the past 4 weeks vs 4 for AMPH).
- JNJ has more recent analyst coverage (25 ratings vs 13 for AMPH).
- Company
- Amphastar Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $21.44+2.05%
- $227.47-1.37%
- Market cap
- $1.25B
- $452.25B
- 1M return
- +9.61%
- -5.19%
- 1Y return
- -12.10%
- +46.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 4
- 13
- Recent ratings
- 13
- 25
Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest AMPH
- Amphastar Pharmaceuticals downgraded by Jefferies with a new price target
- SEC Form DEFA14A filed by Amphastar Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Amphastar Pharmaceuticals Inc.
- Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.
- EVP CORP ADMIN CENTER Liawatidewi Yakob covered exercise/tax liability with 1,033 shares, decreasing direct ownership by 0.84% to 121,892 units (SEC Form 4)
- SENIOR EVP, PRODUCTION CENTER Zhou Rong covered exercise/tax liability with 1,225 shares, decreasing direct ownership by 0.71% to 171,554 units (SEC Form 4)
- CFO, EVP & TREASURER Peters William J covered exercise/tax liability with 1,973 shares, decreasing direct ownership by 1% to 175,063 units (SEC Form 4)
- CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. covered exercise/tax liability with 12,692 shares, decreasing direct ownership by 0.33% to 2,990,052 units (SEC Form 4)
- Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision